1Professor of Plastic Surgery, Faculty of Medicine, Cairo University, Egypt
2Professor of General Surgery, National Laser Institute, Cairo University, Egypt
3Specialist of Plastic Surgery, Department of Plastic Surgery, Matariateaching Hospital, Cairo, Egypt
4Asissatant Professor of Plastic Surgery, Faculty of Medicine, Cairo University, Egypt
5Specialistof Plastic Surgery, Nasser Institute Hospital, Cairo, Egypt
*Corresponding author: Ahmed Hosny Nada, Specialist of Plastic Surgery, Department of Plastic Surgery, Mataria teaching Hospital, Cairo, Egypt, E-mail: drahmdnada@gmail.com
Online published on 31 March, 2020.
Is to evaluate the results of intralesional bleomycin injection for treatment of haemangiomaand vascular malformation. Indications, limitations, adjustment of dose and results of treatment
This study was carried out on 40 patients with vascular anomalies; either hemangioma or vascular malformations from both sexes at different age groups. Patients treated with intralesional Bleomycin Injection and treatment response will be evaluated
26 cases (65%) present significant response which includes complete resolution, excellent and good response; 7 cases (17.5%) presents fair response and 7 cases (17.5%) presents poor response. No cases presents no change or increase in size
Intralesional bleomycin injection (IBI) is a simple, practical and noninvasive method of treatment of vascular anomalies and can considered one of priorities in the treatment of Infantile Hemangiomas and small and medium sized venous malformations.
Vascular anomalies, Infantile Hemangioma (IH), vascular malformation, Bleomycin and Intralesional Bleomycin Injection (IBI)
